(Boursier.com) — Alongside founding director Daniel Eclache, Turenne Santé entered the capital of Phodé as part of an operation allowing the entry of senior executives and the exit of minority shareholders in order to support the Group in the growth of its business.
Founded in 1996 by Daniel Eclache, Phodé is the first laboratory specializing in olfaction and involved in the design, production and marketing of natural sensory solutions for the well-being of humans, animals and the environment. .
With more than 20 ME in turnover, the Group has experienced a phase of rapid development since its creation with 10% growth per year over the past ten years. Its success is based on an economic model reconciling research and development and commercial expansion. Present internationally, the Phodé Group generates 70% of its sales outside the borders of France by relying on its networks of distributors and its subsidiaries in China, South Africa and Canada, another differentiating axis of the Group.
With the entry of Turenne Santé, Phodé is writing a new page in its development by allowing the exit of historical shareholders (including the investment fund Oraxys Environment 1) and the increase in the capital of the management team led by Damien Guillobez , new Managing Director of Phodé. The Group wishes to pursue its growth dynamic through an ambitious business plan with the objective of doubling turnover by 2026.
This investment is the eighth operation in less than three years for the FPCI Capital Santé 2, which has €185 million under management. As a reminder, the strategy of Capital Santé 2 aims to support growth and respond to the challenges of transmission of profitable French SMEs and ETIs present in the health sector.
This transaction is the seventh successful disposal of the Oraxys Environment 1 fund dedicated to European SMEs with an offer of value-added products/services for the environment, public health or resource efficiency.
©2022 Boursier.com